Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod

References

• Peterson LK, Fujinami RS. Inflammation, demyelination, neurodegeneration and neuroprotection in the pathogenesis of multiple sclerosis. J Neuroimmunol 2007;184:37-44
   PubMed Web of Science ®Google Scholar
• Alonso A, Jick SS, Olek MJ, et al. Incidence of multiple sclerosis in the United Kingdom: findings from a population-based cohort. J Neurol 2007;254:1736-41
   PubMed Web of Science ®Google Scholar
• Williamson DM, Henry JP, Schiffer R, et al. Prevalence of multiple sclerosis in 19 Texas counties, 1998–2000. J Environ Health 2007;69:41-5
   PubMed Web of Science ®Google Scholar
• Multiple Sclerosis International Federation. London: Multiple Sclerosis International Federation. Atlas of MS Database, 2008. Available at: http://www.atlasofms.org/[Last accessed 17 Aug 2011]
   Google Scholar
• Richards RG, Sampson FC, Beard SM, et al. A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models. Health Technol Assess 2002;6:1-73
   PubMedGoogle Scholar
• Aronson KJ. Quality of life among persons with multiple sclerosis and their caregivers. Neurology 1997;48:74-80
   PubMed Web of Science ®Google Scholar
• Green G, Todd J. ‘Restricting choices and limiting independence’: social and economic impact of multiple sclerosis upon households by level of disability. Chronic Illn 2008;4:160-72
   PubMedGoogle Scholar
• Tremlett HL, Luscombe DK, Wiles CM. Prescribing for multiple sclerosis patients in general practice: a case–control study. J Clin Pharm Ther 2001;26:437-44
   PubMed Web of Science ®Google Scholar
• Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 2003;61:1528-32
   PubMed Web of Science ®Google Scholar
• Drugs at FDA. Novartis Pharmaceuticals Corp., Approved 2010 September 21. Gilenya (fingolimod): prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022527s000lbl.pdf [Last accessed 17 Aug 2011]
   Google Scholar
• European Medicines Agency. London: European Medicinces Agency, 17 February 2011. Assessment Report: Gilenya. Procedure No. EMEA/H/C/2202. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002202/WC500104529.pdf [Last accessed 17 Aug 2011]
   Google Scholar
• Health Canada Drug Product Database Online Query. Dorval, Canada: Novartis Pharmaceuticals Canada Inc., Revised 21 March 2011. Product Monograph: Gilenya (Fingolimod). Available at: http://webprod3.hc-sc.gc.ca/dpd-bdpp/start-debuter.do?lang=eng [Last accessed 16 Aug 2011]
   Google Scholar
• Cohen JA, Barkhof F, Comi G, et al.; TRANSFORMS Study Group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15
   PubMed Web of Science ®Google Scholar
• Kappos L, Radue EW, O’Connor P, et al.; FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401
   PubMed Web of Science ®Google Scholar
• Freedman MS, Hughes B, Mikol DD, et al. Efficacy of disease-modifying therapies in relapsing remitting multiple sclerosis: a systematic comparison. Eur Neurol 2008;60:1-11
   PubMed Web of Science ®Google Scholar
• Goodin DS. Disease-modifying therapy in multiple sclerosis: update and clinical implications. Neurology 2008;71(24 Suppl 3):S8-13
   PubMed Web of Science ®Google Scholar
• Nikfar S, Rahimi R, Abdollahi M. A meta-analysis of the efficacy and tolerability of interferon-beta in multiple sclerosis, overall and by drug and disease type. Clin Ther 2010;32:1871-88
   PubMed Web of Science ®Google Scholar
• Oliver BJ, Kohli E, Kasper LH. Interferon therapy in relapsing-remitting multiple sclerosis: a systematic review and meta-analysis of the comparative trials. J Neurol Sci 2011;302:96-105
   PubMed Web of Science ®Google Scholar
• Centre for Reviews and Dissemination. York, UK: University of York, January 2009. Systematic Reviews: CRD’s Guidance for Undertaking Reviews in Health Care. Available at: http://www.york.ac.uk/inst/crd/SysRev/!SSL!/WebHelp/SysRev3.htm [Last accessed 16 Aug 2011]
   Google Scholar
• Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12
   PubMedGoogle Scholar
• Higgins JPT, Green S (eds.) Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009
   Google Scholar
• Roskell NS, Lip GY, Noack H, et al. Treatments for stroke prevention in atrial fibrillation: a network meta-analyses and indirect comparisons versus dabigatran etexilate. Thromb Haemost 2010;104:1106-15
   PubMed Web of Science ®Google Scholar
• Thorlund K, Wells GA, Bliddal H et al. Frequentist and Bayesian multiple-treatments meta-analyses of rare events: risk of malignancies following anti-TNF therapy in rheumatoid arthritis patients. 17th Cochrane Colloquium, Singapore, 11–14 October 2009: Abstract P10-3. Available at: Cochrane Colloquim abstracts at http://www.imbi.uni-freiburg.de/OJS/cca/index.php/cca/article/viewArticle/8072 [Last accessed 17 Aug 2011]
   Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009;62:1006-12
   PubMed Web of Science ®Google Scholar
• O’Connor P, Filippi M, Arnason B, et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomized, multicentre study. Lancet Neurol 2009;8:889-97. Errata in: Lancet Neurol 2009;8:981. Lancet Neurol 2011;10:115
   PubMed Web of Science ®Google Scholar
• Cadavid D, Wolansky LJ, Skurnick J, et al. Efficacy of treatment of MS with IFN beta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology 2009;72:1976-83
   PubMed Web of Science ®Google Scholar
• Mikol DD, Barkhof F, Chang P, et al.; REGARD study group. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomized, parallel, open-label trial. Lancet Neurol 2008;7:903-14
   PubMed Web of Science ®Google Scholar
• Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology 2002;59:1496-506
   PubMed Web of Science ®Google Scholar
• Durelli L, Verdun E, Barbero P, et al.; Independent Comparison of Interferon (INCOMIN) Trial Study Group. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomized multicentre study (INCOMIN). Lancet 2002;359:1453-60
   PubMed Web of Science ®Google Scholar
• Ebers GC, Hommes O, Hughes RAC, et al.; PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-504. Erratum in: Lancet 1999;353:678
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-94
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing–remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995;45:1268-76
   PubMed Web of Science ®Google Scholar
• IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing–remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-61
   PubMed Web of Science ®Google Scholar
• Bornstein MB, Miller A, Slagle S, et al. A pilot trial of Cop 1 in exacerbating–remitting multiple sclerosis. N Engl J Med 1987;317:408-14
   PubMed Web of Science ®Google Scholar
• Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 2001;49:290-7
   PubMed Web of Science ®Google Scholar
• Saida T, Tashiro K, Itoyama Y, et al.; Interferon Beta-1b Multiple Sclerosis Study Group of Japan. Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study. Neurology 2005;64:621-30
   PubMed Web of Science ®Google Scholar
• Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-31
   PubMed Web of Science ®Google Scholar
• Schumacker GA, Beebe G, Kibler RF, et al. Problems of experimental trials of therapy in multiple sclerosis: report by the Panel on the Evaluation of Experimental Trials of Therapy in Multiple Sclerosis. Ann N Y Acad Sci 1965;122:552-68
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Cookfair DL, Rudick RA, et al. A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating–remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis Collaborative Research Group (MSCRG). Mult Scler 1995;1:118-35
   PubMedGoogle Scholar
• Limmroth V, Malessa R, Zettl UK, et al.; QUASIMS Study Group. Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing–remitting multiple sclerosis. J Neurol 2007;254:67-77
   PubMed Web of Science ®Google Scholar
• Rice GPA, Incorvaia B, Munari LM, et al. Interferon in relapsing–remitting multiple sclerosis. Cochrane Database Syst Rev 2001;(4):CD002002. DOI: 10.1002/14651858.CD002002
   Google Scholar
• Inusah S, Sormani MP, Cofield SS, et al. Assessing changes in relapse rates in multiple sclerosis. Mult Scler 2010;16:1414-21
   PubMed Web of Science ®Google Scholar
• Nicholas R, Straube S, Schmidli H, et al. Trends in annualized relapse rates in relapsing–remitting multiple sclerosis and consequences for clinical trial design. Mult Scler 2011;17:1211-17
   PubMed Web of Science ®Google Scholar
• Jones B, Roger J, Lane PW, et al.; on behalf of PSI Health Technology Special Interest Group, Evidence Synthesis sub-team. Statistical approaches for conducting network meta-analysis in drug development. Pharm Stat 2011;10:523-31
   PubMed Web of Science ®Google Scholar